NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that its Cogenics division has completed its work with Rosetta Biosoftware to develop microRNA analysis capabilities for the Rosetta Resolver® Gene Expression Data Analysis System, the leading software system for gene expression data management and analysis. This new capability has been integrated with the Rosetta Resolver system and will be part of the next release of the software, enabling scientists to analyze microRNA expression data alongside gene expression data generated using microarrays.
